Adicet Bio Stock Alpha and Beta Analysis

ACET Stock  USD 0.91  0  0.22%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Adicet Bio. It also helps investors analyze the systematic and unsystematic risks associated with investing in Adicet Bio over a specified time horizon. Remember, high Adicet Bio's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Adicet Bio's market risk premium analysis include:
Beta
0.87
Alpha
(0.55)
Risk
4.69
Sharpe Ratio
(0.15)
Expected Return
(0.72)
Please note that although Adicet Bio alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Adicet Bio did 0.55  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Adicet Bio stock's relative risk over its benchmark. Adicet Bio has a beta of 0.87  . Adicet Bio returns are very sensitive to returns on the market. As the market goes up or down, Adicet Bio is expected to follow. At this time, Adicet Bio's Book Value Per Share is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.51 in 2025, whereas Price Fair Value is likely to drop 0.52 in 2025.

Enterprise Value

(62.75 Million)

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Adicet Bio Backtesting, Adicet Bio Valuation, Adicet Bio Correlation, Adicet Bio Hype Analysis, Adicet Bio Volatility, Adicet Bio History and analyze Adicet Bio Performance.
For more information on how to buy Adicet Stock please use our How to Invest in Adicet Bio guide.

Adicet Bio Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Adicet Bio market risk premium is the additional return an investor will receive from holding Adicet Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Adicet Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Adicet Bio's performance over market.
α-0.55   β0.87

Adicet Bio expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Adicet Bio's Buy-and-hold return. Our buy-and-hold chart shows how Adicet Bio performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Adicet Bio Market Price Analysis

Market price analysis indicators help investors to evaluate how Adicet Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Adicet Bio shares will generate the highest return on investment. By understating and applying Adicet Bio stock market price indicators, traders can identify Adicet Bio position entry and exit signals to maximize returns.

Adicet Bio Return and Market Media

The median price of Adicet Bio for the period between Tue, Oct 22, 2024 and Mon, Jan 20, 2025 is 1.03 with a coefficient of variation of 18.39. The daily time series for the period is distributed with a sample standard deviation of 0.2, arithmetic mean of 1.11, and mean deviation of 0.18. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Adicet Bio to Present at the American College of Rheumatology Convergence 2024
11/05/2024
2
Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
11/18/2024
3
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635
11/29/2024
4
Short Interest in Adicet Bio, Inc. Rises By 6.1 percent - MarketBeat
12/02/2024
5
ACET Stock Dips Amid Biotech Sector Volatility
12/12/2024
6
Acquisition by Peng Katie of 5900 shares of Adicet Bio subject to Rule 16b-3
12/13/2024
7
Adicet Bio appoints Julie Maltzman as chief medical officer
12/18/2024
8
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in MetastaticAdvanced Clear Cell Renal Cell Carcinoma
12/19/2024
9
Adicet Bio, Inc. Short Interest Update - MarketBeat
12/30/2024

About Adicet Bio Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Adicet or other stocks. Alpha measures the amount that position in Adicet Bio has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2020 2024 2025 (projected)
Payables Turnover1.142.672.54
Days Of Inventory On Hand187.05168.35212.06

Adicet Bio Upcoming Company Events

As portrayed in its financial statements, the presentation of Adicet Bio's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adicet Bio's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Adicet Bio's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Adicet Bio. Please utilize our Beneish M Score to check the likelihood of Adicet Bio's management manipulating its earnings.
20th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Adicet Bio

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Adicet Stock Analysis

When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.